AI-EvoYeast Harnessing Genomic Instability with Al-Driven Adaptive Laboratory Evolution for Accelerated Yeast Bioproduction
- Coordinator
- Imperial College of Science Technology and Medicine, United Kingdom
- Runs
- 1 May 2026 to 30 April 2028
- Status
- Running
- EU funding
- €260k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101281441
What the project is doing
In the project's own words, from its summary on CORDIS.
The production of high-volume albumins, essential proteins for therapeutics and sustainable food, faces critical bottlenecks. In medicine, the supply of human serum albumin (HSA) is constrained by a reliance on plasma, which carries pathogen risks and supply vulnerabilities. In the food sector, ovalbumin production via precision fermentation offers a sustainable alternative to animal agriculture. Still, they both require overcoming major yield and cost-effectiveness barriers to be viable at an industrial scale.
To address these challenges, AI-EvoYeast will exploit the inherent instability of polyploid yeast as an engine for accelerated evolution, integrating it with product-coupled selection to drive the evolution of albumin-hyperproducing strains. By employing an unbiased evolutionary approach, the platform enables the cell itself to explore a vast solution space of mutations, gene expression changes, and network-level adaptations, overcoming the stress of protein hyperproduction and the limits of rational design.
The AI-EvoYeast project will develop a next-generation yeast (S. cerevisiae) platform, transforming a biological challenge, genomic instability, into a powerful engineering asset. Unlike traditional Adaptive Laboratory Evolution (ALE), AI-EvoYeast integrates Artificial Intelligence (AI) and Machine Learning (ML), fuelled by multi-omics data, to decipher adaptive mechanisms and build a predictive model for optimal genomic configurations.
Insights from explainable AI (XAI) will then guide precise CRISPR interventions to reconstruct superior phenotypes in a stable industrial chassis. This project pioneers a highly generalisable AI-augmented evolutionary strategy. By creating a predictive platform technology estimated to slash R&D timelines by up to 50%, it will secure a sustainable, cost-effective European supply of vital proteins for the pharmaceutical and food industries.
This directly supports EU strategic autonomy and leadership in the global bioeconomy.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Imperial College of Science Technology and Medicine | London | United Kingdom | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI